[1]李静*,李美林,孙国宏,等.抗血管药物治疗Ⅲ/Ⅳ期和复发性卵巢癌疗效的荟萃分析[J].中国计划生育和妇产科,2018,(6):42-47.
　LI Jing*,LI Mei-lin,SUN Guo-hong,et al.A meta-analysis of the efficacy of anti-angiogenic agents in thetreatment of stage III / IV and recurrent ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(6):42-47.

点击复制

抗血管药物治疗Ⅲ/Ⅳ期和复发性卵巢癌疗效的荟萃分析

分享到：

参考文献/References:

［1］Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential ［J］. Ther Adv Med Oncol, 2014, 6(5): 229-239. ［2］Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer ［J］. Lancet, 2014, 384(9951): 1376-1388. ［3］Baldwin L, Ware R, Huang B, et al. Ten-year relative survival for epithelial ovarian cancer ［J］. Gynecol Oncol, 2011, 121(1, 1): S34-S35. ［4］Tarver T. American Cancer Society Cancer facts & figures 2014 ［J］. J Consum Health Internet, 2012, 16(3): 366-367. ［5］Ledermann JA, Embleton AC, Raja FA, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial ［J］. Lancet, 2016, 387(123): 1066-1074. ［6］Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial ［J］. Lancet Oncology, 2014, 15(8): 799-808. ［7］Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial ［J］. J Clin Oncol, 2014, 32(13): 1302-1308. ［8］Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer ［J］. N Engl J Med, 2011, 365(26): 2473-2483. ［9］Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer［J］. N Engl J Med, 2011, 365(26): 2484-2496. ［10］Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)［J］. Journal of Clinical Oncology, 2011, 29(15, S): A5007. ［11］Herzog TJ, Scambia G, Kim BG, et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma ［J］. Gynecol Oncol, 2013, 130(1): 25-30. ［12］Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data the PRISMA-IPD statement ［J］. JAMA, 2015, 313(16): 1657-1665. ［13］Armijo-Olivo S, Stiles CR, Hagen NA, et al. Assessment of study quality for systematic reviews: a comparison of the cochrane collaboration risk of bias tool and the effective public health practice project quality assessment tool: methodological research［J］. J Eval Clin Pract, 2012, 18(1): 12-18. ［14］Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis［J］. Trials, 2007, 8(1): 16. ［15］Pignata S, Lorusso D, Scambia GA, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial［J］. Lancet Oncology, 2015, 16(5): 561-568. ［16］Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer ［J］. Gynecol Oncol, 2015, 139(1): 10-16. ［17］Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial ［J］. J Clin Oncol, 2014, 32(13): 1302-1308. ［18］Du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer ［J］. Journal of Clinical Oncology, 2014, 32(30):3374-3382. ［19］Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer ［J］. Journal of Clinical Oncology, 2012, 30(4): 362-371. ［20］Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer［J］. Journal of clinical oncology, 2012, 30(17): 2039-2045. ［21］Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer ［J］. Journal of Clinical Oncology, 2011, 29(28): 3798-3804. ［22］Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer［J］. N Engl J Med, 2011, 365(26): 2473-2483. ［23］Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer［J］. N Engl J Med, 2011, 365(26): 2484-2496. ［24］Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer ［J］. Eur J Cancer, 2016, 56(2): 131-143. ［25］Coleman RL, Monk BJ, Sood AK, et al. Latest research and clinical treatment of advanced-stage epithelial ovarian cancer［J］. Nat Rev Clin Oncol, 2013, 10(4): 211-224. ［26］MEI Ling, CHEN Hui, WEI Dong-mei, et al. Maintenance chemotherapy for ovarian cancer［J］. Cochrane Database of Systematic Reviews, 2013, 9(6): D7414.